Toni Choueiri: Our recent perspective on the next therapies in immuno-oncology trials
Toni Choueiri, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, posted on X about recent paper by him as co-author, titled “Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types” published on The Lancet.
Authors: Karl Semaana, Rashad Nawfala, Elizabeth Nally, Yelena Y Janjigian, Caroline Robert, Solange Peters, Thomas Powles, Toni K Choueiri
“Our recent perspective on the next/subsequent therapies in IO neoadj/adj trials. Data is often incomplete, access is variable, reporting is inconsistent and we share a consensus roadmap for clinical trials.”
Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. As a medical oncologist, clinical trialist, and translational researcher, he specializes in treating genitourinary cancers (prostate, bladder, testis, and kidney cancer), with a focus on kidney cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023